FDA turns focus on biologics in spate of warning letters
The three letters point to an enforcement posture toward manufacturers marketing biologics derived from human placentas and umbilical cords.
Premium article
On December 1, the US Food and Drug Administration (FDA) issued a spate of warning letters to drug and biologic manufacturers for marketing unapproved products.
All three letter recipients – BioXtek, Celularity, and Lux Therapeutics – are manufacturers that utilize human cells, tissues, and cellular and tissue-based products (HCT/Ps) in
